-
EP3853227
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3853227
| EP3853227 - QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.01.2024 Database last updated on 25.09.2024 | |
| Former | Examination is in progress Status updated on 17.03.2023 | ||
| Former | Request for examination was made Status updated on 25.06.2021 | ||
| Former | The international publication has been made Status updated on 28.03.2020 | ||
| Former | unknown Status updated on 28.09.2019 | Most recent event Tooltip | 26.01.2024 | Application deemed to be withdrawn | published on 28.02.2024 [2024/09] | Applicant(s) | For all designated states Aprea Therapeutics AB Nobels väg 16 171 65 Solna / SE | [2021/30] | Inventor(s) | 01 /
HAGBERG, Lars c/o Aprea Therapeutics AB Nobels väg 16 171 65 Solna / SE | 02 /
RINGOM, Rune c/o Aprea Therapeutics AB Nobels väg 16 171 65 Solna / SE | 03 /
BLIZZARD, Tim c/o Aprea Therapeutics AB Nobels väg 16 171 65 Solna / SE | [2021/30] | Representative(s) | AWA Sweden AB Box 45086 104 30 Stockholm / SE | [N/P] |
| Former [2021/30] | AWA Sweden AB P.O. Box 45086 104 30 Stockholm / SE | Application number, filing date | 19770092.5 | 20.09.2019 | [2021/30] | WO2019EP75278 | Priority number, date | EP20180195621 | 20.09.2018 Original published format: EP 18195621 | EP20180196157 | 24.09.2018 Original published format: EP 18196157 | EP20180196777 | 26.09.2018 Original published format: EP 18196777 | EP20180197436 | 28.09.2018 Original published format: EP 18197436 | [2021/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020058458 | Date: | 26.03.2020 | Language: | EN | [2020/13] | Type: | A1 Application with search report | No.: | EP3853227 | Date: | 28.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.03.2020 takes the place of the publication of the European patent application. | [2021/30] | Search report(s) | International search report - published on: | EP | 26.03.2020 | Classification | IPC: | C07D453/02, A61K31/439, A61P35/00, A61K31/4196 | [2021/30] | CPC: |
A61P35/00 (EP,IL,KR,US);
A61K31/4196 (IL);
C07D453/02 (EP,IL,KR,US);
A61K31/439 (IL,KR,US);
A61K31/444 (US);
A61K31/506 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/30] | Title | German: | CHINUCLIDIN-3-ON-DERIVATE UND DEREN VERWENDUNG ZUR KREBSBEHANDLUNG | [2021/30] | English: | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | [2021/30] | French: | DÉRIVÉS DE QUINUCLIDINE-3-ONE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER | [2021/30] | Entry into regional phase | 15.04.2021 | National basic fee paid | 15.04.2021 | Designation fee(s) paid | 15.04.2021 | Examination fee paid | Examination procedure | 15.04.2021 | Examination requested [2021/30] | 15.04.2021 | Date on which the examining division has become responsible | 30.11.2021 | Amendment by applicant (claims and/or description) | 20.03.2023 | Despatch of a communication from the examining division (Time limit: M06) | 03.10.2023 | Application deemed to be withdrawn, date of legal effect [2024/09] | 24.10.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/09] | Fees paid | Renewal fee | 17.08.2021 | Renewal fee patent year 03 | 16.08.2022 | Renewal fee patent year 04 | 17.08.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IDA]WO2004084893 (APREA AB [SE], et al) [ID] 1-23,68-89 * claim - * [A] 24-45; | [IDA]WO2005090341 (APREA AB [SE], et al) [ID] 1,46-67,90-103 * example 5; claim - *[A] 24-45 | by applicant | US3384641 | US3462442 | US3598825 | US3726877 | WO0224692 | WO03070250 | WO2004084893 | WO2005090341 | WO2007062030 | WO2010090976 | CN104860994 | WO2015150472 | - KOPRIVES, Genes Dev, (19960000), vol. 10, pages 1054 - 1072 | - SHERR, Genes Dev, (19980000), vol. 12, pages 2984 - 2991 | - EVANLITTLEWOOD, Science, (19980000), vol. 281, pages 1317 - 1322 | - GOTTLIEBOREN, Semin Cancer Biol, (19980000), vol. 8, pages 359 - 68 | - GREEN et al., Nature, (20090000), vol. 458, pages 1127 - 1130 | - BEROUDSOUSSI, Nucl Acids Res, (19980000), vol. 26, pages 200 - 204 | - SYMONDS, Cell, (19940000), vol. 78, pages 703 - 711 | - BARDEESY et al., Cancer Res, (19950000), vol. 55, pages 215 - 219 | - LOWE et al., Science, (19940000), vol. 266, pages 807 - 810 | - BYKOV et al., Front Oncol, (20160000), page 6 | - MOUNTZ, Arthritis and Rheumatology, (19940000), vol. 10, pages 1415 - 1420 | - OKUDA et al., J Neuroimmunol, (20030000), vol. 135, pages 29 - 37 | - PENG et al., Cell Death Dis, (20130000), vol. 4, page e881 | - MOHELL et al., Cell Death Dis, (20150000), vol. 6, page e1794 | - LIU et al., Nat Commun, (20170000), vol. 8, page 14844 | - WONDRAK, Antioxid Redox Signal, (20090000), vol. 11, pages 3015 - 3069 | - MALKI et al., Bioorg Chem, (20170000), vol. 72, pages 57 - 63 | - SINGH et al., J Med Chem, (19690000), vol. 12, pages 524 - 526 | - ORAINMATTES, Synlett, (20050000), vol. 19, pages 3008 - 3010 | - SANI et al., Chemistry - A Eur J, (20170000), vol. 23, pages 5842 - 5850 | - DECLERCK et al., J Org Chem, (20040000), vol. 69, pages 8372 - 8381 | - LEE et al., Org Lett, (20160000), vol. 18, pages 3678 - 3681 | - MORIWAKE et al., J Org Chem, (19890000), vol. 54, pages 4114 - 4120 |